New hope for brain cancer patients: drug combo targets aggressive tumors

NCT ID NCT06336291

Ongoing Disease control Sponsor: Philogen S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, L19TNF and lomustine, in 90 adults whose glioblastoma has returned or worsened. The goal is to find the safest and most effective dose to control the tumor and extend survival. Participants must have confirmed glioblastoma and be in adequate health to receive treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Beth Israel Deaconess Medical Center (BIDMC)

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute (DFCI)

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital (MGH)

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
The University of Texas, MD Anderson Cancer Center

Houston, Texas, 77030, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia (UVA)

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.